映恩生物-B今日盘中大涨5.02%，引起了市场的广泛关注。
消息面上，公司于盘前发布公告，董事会已批准发行人民币股份并在科创板上市的计划。公司拟发行不超过1577.92万股人民币股份，占发行后总股本的15%，募集资金将主要用于新药研发及补充营运资金。此举标志着公司正积极构建“H+A”双资本平台，以拓宽融资渠道，支持其全球ADC（抗体偶联药物）管线的临床推进和技术平台建设。
分析认为，A股市场对生物医药等硬科技赛道通常给予更高的流动性和估值溢价，映恩生物此次回A计划有望为公司带来价值重估。此外，公司的核心产品管线进展顺利，并与BioNTech等国际巨头达成多项合作，展现了其在IO2.0+ADC领域的全球领先地位，进一步增强了投资者对其长期增长潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.